This site is intended for healthcare professionals

Merck Inc., announces positive topline results from two phase III adult studies evaluating V114, an investigational 15-valent pneumococcal conjugate vaccine, including pivotal trial.

Read time: 1 mins
Last updated:16th Mar 2021
Published:10th Sep 2020
Condition: Pneumococcal Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest